“…Consequently, despite treatment, in the majority of the patients, T2D deteriorates progressively over time, eventually necessitating insulin supplementation [ 6 , 7 , 8 ]. This progressive clinical deterioration of T2D has inspired the search for new therapeutics that arrest the disease’s progression, protect the remaining pancreatic beta cells, and restore beta-cell mass in T2D by exploiting the inherent plasticity of the pancreas [ 9 , 10 , 11 , 12 , 13 , 14 , 15 ].…”